Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Authors:
Open Access
- 1 January 2014
- journal article
- Published by Korean Breast Cancer Society in Journal of Breast Cancer
- Vol. 17 (1) , 40-46
Abstract
Kim KI, et al. J Breast Cancer. 2014 Mar;17(1):40-46. https://doi.org/10.4048/jbc.2014.17.1.40Keywords
This publication has 16 references indexed in Scilit:
- Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatmentBMC Cancer, 2011
- Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosisBreast Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patientsBritish Journal of Cancer, 2007
- Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour responseThe Lancet Oncology, 2006
- Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary ChemotherapyJournal of Clinical Oncology, 2005
- Proliferation Marker Ki-67 in Early Breast CancerJournal of Clinical Oncology, 2005
- Expression of c‐kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumoursHistopathology, 1999